Cancer

Showing 15 posts of 1067 posts found.

Scientists use cold virus to treat bladder cancer

July 5, 2019
Medical Communications, Research and Development CVA21, Cancer, bladder cancer, oncology, oncolytic, pharma, virus

A strain of the virus that causes the common cold has been found to potentially target, infect and kill cancer …

Cancer cost US more than $94 billion in lost earnings in 2015

July 4, 2019
Research and Development Cancer, economics, health, lost earnings, oncology, pharma

Cancer deaths cost the US economy $94.4 billion in lifetime earnings in 2015, according to figures from the American Cancer …

Hospitals in Oxfordshire to test for susceptibility to dangers of chemotherapy

July 1, 2019
Manufacturing and Production Cancer, Diagnostics, NHS, UK, breast, colon, oesophogus, pharma

Hospitals in Oxfordshire have introduced a genetic test which helps doctors predict the dangerous side effects of chemotherapy.   In …

FDA greenlights Pfizer biosimilar version of Genentech’s Avastin

July 1, 2019
Sales and Marketing Cancer, Genentech, Pfizer, pharma, pncology

Pfizer is celebrating the approval by the FDA of Zirabev, its biosimilar version of Genentech’s Avastin (bevacizumab), which is now …

512px-hpv_causing_cervical_cancer

Major review points to success of HPV vaccine, cervical cancer could be eradicated in developed nations

June 27, 2019
Research and Development Cancer, HPV, UK, cervical cancer, human papilloma virus, pharma, vaccines

A major new review published in The Lancet has supported the effectiveness of the human papilloma virus (HPV) vaccine in …

NICE recommends Amgen’s Blincyto in rare acute lymphoblastic leukaemia sub-population

June 19, 2019
Research and Development, Sales and Marketing Amgen, Cancer, NICE, acute lymphoblastic leukaemia, blincyto, pharma

Patients on the NHS in England and Wales will now be able to access Amgen’s Blincyto (blinatumomab) after NICE reveals …

merck-keytruda

MSD’s Keytruda snatches up first approval in small cell lung cancer

June 19, 2019
Research and Development, Sales and Marketing Cancer, FDA, MSD, US, keytruda, lung cancer, pharma

MSD has revealed that its anti-PD-1 immunotherapy Keytruda (pembrolizumab) has been awarded marketing authorisation from the FDA as a monotherapy …

lynparza

EU approval for MSD and AZ’s Lynparza in first-line BRCA-mutated advanced ovarian cancer

June 18, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, lynparza, ovarian cancer, pharma

AstraZeneca and MSD’s jointly-developed therapy Lynparza (olaparib) has scored its third EU approval, the pair announced, with authorisation for the …

Roche secures world first with Japanese Rozlytrek approval in advanced recurrent solid tumours

June 18, 2019
Manufacturing and Production, Sales and Marketing Cancer, Japan, Roche, Rozlytrek, pharma

Roche’s personalised cancer therapy Rozlytrek (entrectinib) has seen its first approval: the drug has been approved in Japan for the …

J&J and Colgate pay $4.8 million each to woman in California

June 13, 2019
Business Services, Medical Communications Cancer, J&J, JJ, lawsuit, pharma, talc

A California court has said Johnson & Johnson and Colgate-Palmolive must pay a total of nearly $10 million to a …

shutterstock_159488225

Darzalex combo makes strong Phase 3 showing in multiple myeloma

June 4, 2019
Manufacturing and Production, Research and Development ASCO 2019, Cancer, Janssen, darzalex, multiple myeloma, pharma

Janssen joined its contemporaries at the 55th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in the release …

amgen_flag

Amgen’s novel KRAS inhibitor monotherapy shows promise at Phase 1 in advanced solid tumours

June 4, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, KRAS

Amgen has unveiled the first clinical data for its investigational KRAS inhibitor AMG 510, the first such therapy to reach …

janssen_latest_logo_on_sign_closer

Janssen’s Erleada combo smashes endpoints in advanced hormone-sensitive prostate cancer

June 3, 2019
Research and Development, Sales and Marketing ASCO 2019, Cancer, Erleada, Janssen, prostate cancer

Janssen joined the showing at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago to present new …

Isatuximab improves on standard of care treatments for multiple myeloma

June 3, 2019
Sales and Marketing Cancer, Immunogen, Sanofi, isatuximab, multiple myeloma, pharma

Sanofi and ImmunoGen’s isatuximab combination therapy prolonged progression free survival by five months compared to standard of care treatments in …

Novartis’ Kisqali combo boosts survival in HR+/HER2- advanced breast cancer

June 3, 2019
Research and Development, Sales and Marketing Cancer, Kisqali, Novartis, breast cancer, pharma

Novartis took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to reveal new Phase 3 …

The Gateway to Local Adoption Series

Latest content